Ipsen has not given up on rare disease drug palovarotene

26 March 2020

Ipsen (Euronext: IPN) shares began trading around 2% higher on Thursday morning, after the French biotech announced today it would restart the global Phase III MOVE trial, in people over the age of 14.

The study is investigating palovarotene, a RARγ selective agonist, in people with fibrodysplasia ossificans progressiva (FOP), an ultra-rare, severely disabling disorder.

The firm’s stock price slumped in late December after the trial was paused, based on a futility analysis suggesting it was unlikely to meet its primary endpoint.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK